Demographic and baseline characteristics
| . | Blinatumomab randomization (N = 271) . | Blinatumomab consolidation (N = 86) . | Blinatumomab maintenance (N = 36) . |
|---|---|---|---|
| Sex, n (%) | |||
| Male | 162 (60.0) | 43 (50.0) | 18 (50.0) |
| Female | 109 (40.0) | 43 (50.0) | 18 (50.0) |
| Race, n (%) | |||
| White | 228 (84.0) | 72 (83.7) | 33 (91.7) |
| Asian | 19 (7.0) | 7 (8.1) | 2 (5.6) |
| Black (or African American) | 5 (2.0) | 2 (2.3) | 0 (0) |
| American Indian or Alaska Native | 0 (0) | 1 (1.2) | 0 (0) |
| Other | 19 (7.0) | 4 (4.7) | 1 (2.8) |
| Median age, y (range) | 37 (18-80) | 38.5 (19-80) | 34 (19-80) |
| Age group, y, n (%) | |||
| <35 | 124 (46.0) | 38 (44.2) | 19 (52.8) |
| 35 to 54 | 80 (30.0) | 26 (30.2) | 12 (33.3) |
| 55 to 64 | 34 (13.0) | 9 (10.5) | 2 (5.6) |
| ≥65 | 33 (12.0) | 13 (15.1) | 3 (8.3) |
| ECOG performance status, n (%) | |||
| 0 | 96 (35.4) | 38 (44.2) | 13 (36.1) |
| 1 | 134 (49.4) | 37 (43) | 19 (52.8) |
| 2 | 41 (15.1) | 11 (12.8) | 4 (11.1) |
| >2 | 0 (0) | 0 (0) | 0 (0) |
| Patients with prior HSCT, n (%) | 94 (35.0) | 38 (44.2) | 24 (66.7) |
| Patients who relapsed after HSCT, n (%) | 91 (34.0) | 36 (41.9) | 23 (63.9) |
| Prior number of salvage regimens, n (%) | |||
| 0 | 114 (42.0) | 46 (53.5) | 20 (55.6) |
| 1 | 91 (34.0) | 22 (25.6) | 11 (30.6) |
| 2 | 45 (17.0) | 13 (15.1) | 3 (8.3) |
| 3 | 14 (5.0) | 3 (3.5) | 2 (5.6) |
| >3 | 7 (3.0) | 2 (2.3) | 0 (0) |
| . | Blinatumomab randomization (N = 271) . | Blinatumomab consolidation (N = 86) . | Blinatumomab maintenance (N = 36) . |
|---|---|---|---|
| Sex, n (%) | |||
| Male | 162 (60.0) | 43 (50.0) | 18 (50.0) |
| Female | 109 (40.0) | 43 (50.0) | 18 (50.0) |
| Race, n (%) | |||
| White | 228 (84.0) | 72 (83.7) | 33 (91.7) |
| Asian | 19 (7.0) | 7 (8.1) | 2 (5.6) |
| Black (or African American) | 5 (2.0) | 2 (2.3) | 0 (0) |
| American Indian or Alaska Native | 0 (0) | 1 (1.2) | 0 (0) |
| Other | 19 (7.0) | 4 (4.7) | 1 (2.8) |
| Median age, y (range) | 37 (18-80) | 38.5 (19-80) | 34 (19-80) |
| Age group, y, n (%) | |||
| <35 | 124 (46.0) | 38 (44.2) | 19 (52.8) |
| 35 to 54 | 80 (30.0) | 26 (30.2) | 12 (33.3) |
| 55 to 64 | 34 (13.0) | 9 (10.5) | 2 (5.6) |
| ≥65 | 33 (12.0) | 13 (15.1) | 3 (8.3) |
| ECOG performance status, n (%) | |||
| 0 | 96 (35.4) | 38 (44.2) | 13 (36.1) |
| 1 | 134 (49.4) | 37 (43) | 19 (52.8) |
| 2 | 41 (15.1) | 11 (12.8) | 4 (11.1) |
| >2 | 0 (0) | 0 (0) | 0 (0) |
| Patients with prior HSCT, n (%) | 94 (35.0) | 38 (44.2) | 24 (66.7) |
| Patients who relapsed after HSCT, n (%) | 91 (34.0) | 36 (41.9) | 23 (63.9) |
| Prior number of salvage regimens, n (%) | |||
| 0 | 114 (42.0) | 46 (53.5) | 20 (55.6) |
| 1 | 91 (34.0) | 22 (25.6) | 11 (30.6) |
| 2 | 45 (17.0) | 13 (15.1) | 3 (8.3) |
| 3 | 14 (5.0) | 3 (3.5) | 2 (5.6) |
| >3 | 7 (3.0) | 2 (2.3) | 0 (0) |